DK2994160T3 - Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g - Google Patents

Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g Download PDF

Info

Publication number
DK2994160T3
DK2994160T3 DK14730660.9T DK14730660T DK2994160T3 DK 2994160 T3 DK2994160 T3 DK 2994160T3 DK 14730660 T DK14730660 T DK 14730660T DK 2994160 T3 DK2994160 T3 DK 2994160T3
Authority
DK
Denmark
Prior art keywords
poolet
alzheimer
immunoglobulin
treatment
subpopulations
Prior art date
Application number
DK14730660.9T
Other languages
Danish (da)
English (en)
Inventor
David M Gelmont
Julia Singer
Sandor Fritsch
Hans-Peter Schwarz
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Application granted granted Critical
Publication of DK2994160T3 publication Critical patent/DK2994160T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14730660.9T 2013-05-06 2014-05-05 Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g DK2994160T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US201361886464P 2013-10-03 2013-10-03
PCT/US2014/036848 WO2014182631A1 (en) 2013-05-06 2014-05-05 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Publications (1)

Publication Number Publication Date
DK2994160T3 true DK2994160T3 (da) 2019-08-12

Family

ID=50943566

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14730660.9T DK2994160T3 (da) 2013-05-06 2014-05-05 Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g

Country Status (12)

Country Link
US (3) US20140328856A1 (https=)
EP (2) EP2994160B1 (https=)
JP (1) JP6424210B2 (https=)
AU (4) AU2014262890B2 (https=)
DK (1) DK2994160T3 (https=)
ES (1) ES2740127T3 (https=)
HR (1) HRP20191383T1 (https=)
HU (1) HUE044737T2 (https=)
LT (1) LT2994160T (https=)
PL (1) PL2994160T3 (https=)
PT (1) PT2994160T (https=)
WO (1) WO2014182631A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP4275750B1 (en) * 2015-09-10 2026-05-06 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
US20190016791A1 (en) * 2016-01-20 2019-01-17 Genentech, Inc. High dose treatments for alzheimer's disease
LT3484502T (lt) * 2016-08-18 2021-12-10 Alkahest, Inc. Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė
MX2019012795A (es) * 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
US20240018231A1 (en) * 2020-10-30 2024-01-18 Rush University Medical Center Intranasal immunotherapt for the treatment of alzheimer's disease
CA3243602A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
EP1463527A4 (en) 2001-10-04 2005-05-11 Protein Therapeutics Inc USE OF GAMMAGLOBULIN FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES
US20060188496A1 (en) 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US8852585B2 (en) * 2006-01-30 2014-10-07 Grifols Therapeutics Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
CN102946799A (zh) * 2010-04-13 2013-02-27 巴克斯特国际公司 脑室增大率在阿尔茨海默病的静脉内免疫球蛋白治疗中的应用
JP2013526518A (ja) * 2010-05-13 2013-06-24 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
US20120076779A1 (en) * 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
JP2014507649A (ja) * 2011-01-18 2014-03-27 バクスター・インターナショナル・インコーポレイテッド ヒト血液中の抗βアミロイド抗体の測定
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
KR101956585B1 (ko) * 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법

Also Published As

Publication number Publication date
PT2994160T (pt) 2019-08-07
LT2994160T (lt) 2019-08-26
US20190144530A1 (en) 2019-05-16
AU2019202459B2 (en) 2020-07-23
AU2014262890A1 (en) 2015-11-26
US20140328856A1 (en) 2014-11-06
HUE044737T2 (hu) 2019-11-28
HRP20191383T1 (hr) 2020-02-07
ES2740127T3 (es) 2020-02-05
AU2014262890B2 (en) 2019-01-31
PL2994160T3 (pl) 2019-10-31
EP3552624A1 (en) 2019-10-16
JP6424210B2 (ja) 2018-11-14
AU2020257034A1 (en) 2020-11-12
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
JP2016518411A (ja) 2016-06-23
WO2014182631A1 (en) 2014-11-13
EP2994160A1 (en) 2016-03-16
US20210238267A1 (en) 2021-08-05
EP2994160B1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
DK2994160T3 (da) Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g
IL285722A (en) Methods for treating alzheimer's disease
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
DK2955195T3 (da) Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
EP2970511A4 (en) INSULIN CONJUGATES incretin
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
EP2932645A4 (en) VALIDATION OF THE SAFETY OF A CENTRAL CLOUD APPLICATION
DK3010506T3 (da) Pridopidin i behandling af huntingtons sygdom
EP2956047A4 (en) IRIS EXPANDER
DK2968208T3 (da) Behandling af kataplexi
EP3065624A4 (en) AUTOMATED DETECTION OF EYE ALIGNMENT
EP2964658A4 (en) SUBSTITUTED ORGANOFLUORBORATES AS IMAGING AGENTS
EP2983654A4 (en) Treatment of cancer using coenzyme q10 combination therapies
EP3379317A4 (en) IMAGING LENS
EP2997047A4 (en) heparansulphates
EP3291722A4 (en) IMPROVED LENS OPPORTER
PL2961426T3 (pl) Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g
EP2959219A4 (en) Class 1 compliant lens assembly
HUE059507T2 (hu) BAFF-ra és B7RP1-re specifikus fehérjék és alkalmazásuk
DK3024816T3 (da) Ppar-sparende forbindelser til behandling af metaboliske sygdomme
DK3041831T3 (da) Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom
EP2976864A4 (en) RECOMMENDATIONS
DK3066475T3 (da) Biomarkører for progression af alzheimers sygdom